Genmab — December 2017
-
Samtidig med Genmabs R&D i nat holder IMF konference om det sidste nye i MM med bl.a. Paul Richardson. Her bliver med garanti også snakket car-t. Streames live. https://www.youtube.com/watch?v=oqA2H5Q-YmQ
-
Sidste udtalelse fra Novod om c-t: .We continue to believe that the CAR-T data looks good, but also that the competition in earlier lines of MM will likely be quite limited and that CAR-T initially will also be restrained by the high cost (up to USD 1-1.5m per patient), which at least will keep the main use for the highly refractory patient population with very limited treatment options. Hence, we also still expect a significant rebound in a stock like Genmab when the CAR-T hype settles a bit
-
-
haha - prøv at få den igennem NICE's evalueringsmodel...
-
https://en.m.wikipedia.org/wiki/Dendreon Similarities
-
http://files.shareholder.com/downloads/AMDA-KPIBN/3691997971x0x966333/8815E418-E24F-48D8-9137-B552120120C5/Chari_MMY1001_D-KRd.pdf 91% VGPR or better in first line. But MRD at same level as ALCYONE.
-
Det er svært at se car-t der
-
Mono smoldering er ikke daras styrke i mono http://files.shareholder.com/downloads/AMDA-KPIBN/3691997971x0x966352/72AB296C-DF10-4895-BFF3-302682BB24FC/Hofmeister_SMM2001_10Dec17_0947.pdf
-
Ja, men det var først efter ASCT. Før ASCT var MRDneg 38% https://ash.confex.com/ash/2017/webprogram/Paper102714.html
-
https://clinicaltrials.gov/ct2/show/NCT03224507?cond=NCT03224507&rank=1 Ja tror at man i dette forsøg prøver at lægge dara oven på.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind